SJIA Foundation Impact via Support of Research
Publications SJIA Foundation has participated in (2018 – 2024)
The foundation has impacted research in SJIA and MAS by actively participating in some research publications and supporting other projects with patient recruitment, giving patient perspective. Here is a list of publications that the foundation has been involved with in the last six years.
2024
- Sinha, R., De Benedetti, F., Grom, A.A. et al. Proceedings from the 4th NextGen Therapies for SJIA and MAS virtual symposium held February 13–14, 2022. Pediatr Rheumatol 21 (Suppl 1), 91 (2023). https://doi.org/10.1186/s12969-023-00863-2
- Nigrovic, P.A., de Benedetti, F., Kimura, Y. et al. The 4th NextGen Therapies for SJIA and MAS: part 1 the elephant in the room: diagnostic/classification criteria for systemic juvenile idiopathic arthritis and adult-onset still’s disease. Pediatr Rheumatol 21 (Suppl 1), 114 (2023). https://doi.org/10.1186/s12969-023-00864-1
- Schulert, G., Vastert, S.J. & Grom, A.A. The 4th NextGen therapies for SJIA and MAS: part 2 phenotypes of refractory SJIA and the landscape for clinical trials in refractory SJIA. Pediatr Rheumatol 21 (Suppl 1), 87 (2023). https://doi.org/10.1186/s12969-023-00865-0
- de Benedetti, F., Grom, A.A. & Brunner, H. The 4th NextGen therapies for SJIA and MAS: part 3 clinical trials in refractory SJIA: historic controls as an alternative to a withdrawal design study. Pediatr Rheumatol 21 (Suppl 1), 150 (2023). https://doi.org/10.1186/s12969-023-00866-z
- Canna, S.W., De Benedetti, F. The 4th NextGen therapies of SJIA and MAS, part 4: it is time for IL-18 based trials in systemic juvenile idiopathic arthritis?. Pediatr Rheumatol 21 (Suppl 1), 79 (2023). https://doi.org/10.1186/s12969-023-00867-y
- Grom, A.A., Canna, S.W., Abu-Arja, R.F. et al. Part 5: Allogeneic HSCT in refractory SJIA with lung disease; recent cases from centers in North America & Europe. Pediatr Rheumatol 21 (Suppl 1), 86 (2023). https://doi.org/10.1186/s12969-023-00868-x
2023
- Shakoory B, Geerlinks A, Wilejto M, et al. The 2022 EULAR/ACR points to consider at the early stages of diagnosis and management of suspected haemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS). Ann Rheum Dis. 2023;82(10):1271-1285. doi:10.1136/ard-2023-224123
- Verweyen EL, Thakkar K, Dhakal S, et al. Population-level single-cell genomics reveals conserved gene programs in systemic juvenile idiopathic arthritis. J Clin Invest. 2023;133(22):e166741. Published 2023 Nov 15. doi:10.1172/JCI166741
- Erkens R., Calis J, Verwoerd A, et al. Recombinant Interleukin-1 Receptor Antagonist Is an Effective First-Line Treatment Strategy in New-Onset Systemic Juvenile Idiopathic Arthritis, Irrespective of HLA-DRB1 Background and IL1RN Variants. Arthritis Rheumatol, 76: 119-129. Published 2023 Jul 20. https://doi.org/10.1002/art.42656
- Maheswaranathan M, Miller B, Ung N, et al. Patient perspectives on telemedicine use in rheumatology during the COVID-19 pandemic: survey results from the COVID-19 Global Rheumatology Alliance. Clin Rheumatol 43, 543–552 (2024). https://doi.org/10.1007/s10067-023-06717-2
- Marques MC, Paul S, Lake C, et al. “Online survey of COVID-19 immunization and infection in patients with systemic juvenile idiopathic arthritis and adult-onset still’s disease.”. Pediatr Rheumatol Online J. 2023;21(1):139. Published 2023 Nov 21. doi:10.1186/s12969-023-00911-x2
2022
- Erkens R, Sinha R, Pickering A, Schulert G, Grom A, van der Veken L, van Deutekom H, Calis J, van Loosdregt J, Vastert S. First Line Treatment Using Recombinant IL-1Receptor Antagonist in New Onset Systemic Juvenile Idiopathic Arthritis Is an Effective Treatment Strategy, Irrespective of HLA DRB1 Background [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/first-line-treatment-using-recombinant-il-1receptor-antagonist-in-new-onset-systemic-juvenile-idiopathic-arthritis-is-an-effective-treatment-strategy-irrespective-of-hla-drb1-background/.
- Chen G, Deutsch G, Schulert G, et al. Identification of Distinct Inflammatory Programs and Biomarkers in Systemic Juvenile Idiopathic Arthritis and Related Lung Disease by Serum Proteome Analysis. Arthritis Rheumatol, 74: 1271-1283. Published 2022 Feb 21 https://doi.org/10.1002/art.42099
- Hausmann J, Kennedy K, Surangiwala S, et al. Early impacts of the COVID-19 pandemic on children with pediatric rheumatic diseases. Eur J Rheumatol. 2022;9(4):185-190. doi:10.5152/eujrheum.2022.21133
- Vega-Fernandez P, Ting T, Mar D, et al. Lung Ultrasound in Children With Systemic Juvenile Idiopathic Arthritis–Associated Interstitial Lung Disease. Arthritis Care Res, 75: 983-988. Published 2022 May 23 https://doi.org/10.1002/acr.24957
- Eloseily E, Chang M, Riordan M, Russell A, Natter M, Kimura Y, Schulert G. Baseline Clinical and Laboratory Features of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Systemic Juvenile Idiopathic Arthritis-Associated Lung Disease (SJIA-LD) Cohort [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/baseline-clinical-and-laboratory-features-of-the-childhood-arthritis-and-rheumatology-research-alliance-carra-systemic-juvenile-idiopathic-arthritis-associated-lung-disease-sjia-ld-cohort/
2021
- Verweyen E, Pickering A, Grom A, Schulert, G (2021), Distinct Gene Expression Signatures Characterize Strong Clinical Responders Versus Nonresponders to Canakinumab in Children With Systemic Juvenile Idiopathic Arthritis. Arthritis Rheumatol, 73: 1334-1340. Published 2021 Jan 16 https://doi.org/10.1002/art.41640
- Schulert G, Pickering A, Do T, et al. Monocyte and bone marrow macrophage transcriptional phenotypes in systemic juvenile idiopathic arthritis reveal TRIM8 as a mediator of IFN-γ hyper-responsiveness and risk for macrophage activation syndromeAnnals of the Rheumatic Diseases 2021;80:617-625 https://ard.bmj.com/content/80/5/617
- Cheung P, Schaffert S, Chang SE, et al. Repression of CTSG, ELANE and PRTN3-mediated histone H3 proteolytic cleavage promotes monocyte-to-macrophage differentiation. Nat Immunol. 2021;22(6):711-722. doi:10.1038/s41590-021-00928-y
- Amigues I, Pearlman AH, Patel A, et al. Coronavirus disease 2019: investigational therapies in the prevention and treatment of hyperinflammation. Expert Rev Clin Immunol. 2020;16(12):1185-1204. doi:10.1080/1744666X.2021.1847084
- Saper VE, Chen G, Deutsch GH, the Childhood Arthritis and Rheumatology Research Alliance Registry Investigators, et al. Emergent high fatality lung disease in systemic juvenile arthritisAnnals of the Rheumatic Diseases 2019;78:1722-1731 https://ard.bmj.com/content/78/12/1722.long
- Yasin S, Fall N, Brown RA, et al. IL-18 as a biomarker linking systemic juvenile idiopathic arthritis and macrophage activation syndrome. Rheumatology (Oxford). 2020;59(2):361-366. doi:10.1093/rheumatology/kez282
- Beukelman T, Tomlinson G, Nigrovic P, Dennos A, Del Gaizo V, Riordan M, Schanberg L, Mohan S, Pfeifer E, Kimura Y. FiRst Line Options for Systemic JIA Treatment (FROST): Results from a Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry Consensus Treatment Plan Observational Study [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/first-line-options-for-systemic-jia-treatment-frost-results-from-a-childhood-arthritis-and-rheumatology-research-alliance-carra-registry-consensus-treatment-plan-observational-study/
2020
- Canna S, Schulert G, de Jesus A, et al. Proceedings from the 2nd Next Gen Therapies for Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome symposium held on October 3-4, 2019. Pediatr Rheumatol 18 (Suppl 1), 53 (2020). https://doi.org/10.1186/s12969-020-00444-7
- Amigues I, Pearlman AH, Patel A, et al. Coronavirus disease 2019: investigational therapies in the prevention and treatment of hyperinflammation. Expert Rev Clin Immunol. 2020;16(12):1185-1204. doi:10.1080/1744666X.2021.1847084
2019
- Schulert GS, Yasin S, Carey B, et al. Systemic Juvenile Idiopathic Arthritis-Associated Lung Disease: Characterization and Risk Factors. Arthritis Rheumatol. 2019;71(11):1943-1954. doi:10.1002/art.41073
- Saper VE, Chen G, Deutsch GH, the Childhood Arthritis and Rheumatology Research Alliance Registry Investigators, et al. Emergent high fatality lung disease in systemic juvenile arthritisAnnals of the Rheumatic Diseases 2019;78:1722-1731 https://ard.bmj.com/content/78/12/1722.long
- Yasin S, Fall N, Brown RA, et al. IL-18 as a biomarker linking systemic juvenile idiopathic arthritis and macrophage activation syndrome. Rheumatology (Oxford). 2020;59(2):361-366. doi:10.1093/rheumatology/kez282
2018
- Brown RA, Henderlight M, Do T, et al. Neutrophils From Children With Systemic Juvenile Idiopathic Arthritis Exhibit Persistent Proinflammatory Activation Despite Long-Standing Clinically Inactive Disease. Front Immunol. 2018;9:2995. Published 2018 Dec 18. doi:10.3389/fimmu.2018.02995
- Beukelman T, Tomlinson G, Nigrovic P, Dennos A, Del Gaizo V, Riordan M, Schanberg L, Mohan S, Pfeifer E, Kimura Y. FiRst Line Options for Systemic JIA Treatment (FROST): Results from a Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry Consensus Treatment Plan Observational Study [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/first-line-options-for-systemic-jia-treatment-frost-results-from-a-childhood-arthritis-and-rheumatology-research-alliance-carra-registry-consensus-treatment-plan-observational-study/